ADXS — Ayala Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $1.28m
- $4.21m
- $0.01m
Annual income statement for Ayala Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 October 31st | 2020 October 31st | 2021 October 31st | 2022 October 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 20.9 | 0.253 | 3.24 | 0.25 | 0.013 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 40.5 | 26.8 | 22 | 19.6 | 36.3 |
| Operating Profit | -19.6 | -26.5 | -18.8 | -19.3 | -36.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -16.6 | -26.4 | -17.8 | -14.3 | -52 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -16.6 | -26.5 | -17.9 | -14.4 | -48.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -16.6 | -26.5 | -17.9 | -14.4 | -48.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -16.6 | -26.5 | -17.9 | -15.4 | -48.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -78.8 | -32.3 | -11 | -7.31 | -7.99 |